ClinicalTrials.gg
Not yet recruitingNCT06505252Updated Jul 17, 2024

Comparison of Topical Use of Platelet-rich Plasma Versus Hyaluronic Acid During Endoscopic Fat Graft Myringoplasty: a Randomized Clinical Study

An interventional study of enoscopic Myringoplasty in Chronic Suppurative Otitis Media, sponsored by Assiut University. Not yet recruiting. Open to participants aged 14 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-07-17.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
14 Years to 50 Years
Sex
All
01

Study summary

This study aimed to compare the effect of adding HA versus PRP to endoscopic FGM in cases of small or medium-sized central TM perforation in the form of:

  1. Evaluation of the graft uptake rate.
  2. Evaluation and comparing audiological outcomes.
  3. Finding out intraoperative and postoperative morbidity.
Read the detailed description

Tympanic membrane (TM) perforations result in recurrent middle ear infection and hearing loss. Both these hazards can be prevented by the reconstructive surgery of the tympanic membrane.

Fat graft myringoplasty (FGM) has been reported as a suitable procedure to close long-standing TM perforations FGM is an efficient, safe and potentially fast method for TM perforation repairing with a success rate varies from 79% to 91%..Many researches was done to use supporting material in myringoplasty Saliba et al used hyaluronic acid fat graft myringoplasty [HAFGM] and results in a higher success rate than using FGM alone. El-Anwar et al proved that Topical autologous platelet-rich plasma(PRP) application during myringolpasty is safe, efficient and enhances healing of TM perforation PRP includes many autologous growth factors that have significant functions like cell proliferation, migration, and angiogenesis. Fibrin and fibronectin are essential proteins in PRP that provide the structural support needed for the cell migration, cell proliferation, and 3-dimensional growth of tissues.

HA has been shown to play a role in cellular signaling, leukocyte growth and migration, Cell adhesion and biological remodeling and is mainly involved in tissue healing with a central role in modulating inflammatory responses also, Its absorption of water causes expansion in volume and formation of a viscoelastic gel which constitutes a favorable scaffold for tissue regeneration and remodeling .

02

Conditions studied

  • Chronic Suppurative Otitis Media

Keywords

  • CSOM
  • chronic suppurative otitis media
  • tympanic membrane perforation
  • TM perforation
  • myringoplasty
  • tympanoplasty
  • endoscopic tympanoplasty
03

In context

Tympanic Membrane Perforation

53 studies on the registry are indexed under Tympanic Membrane Perforation; 14 are open to participants now.

This study's planned enrollment of 60 is close to the median of 57 across 39 interventional studies indexed under Tympanic Membrane Perforation.

Browse Tympanic Membrane Perforation studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with central small or median sized dry perforation
  • Aged between 14 and 50 years
  • In cases of CSOM the perforation must be dry with no otorrhea with healthy middle ear mucosa for at least three month without medications
  • Conductive gap on audiometry not more than 40 dB.

Exclusion criteria

Exclusion Criteria:

  • Discharging CSOM .
  • Concurrent URTI .
  • CSOM with dry marginal perforation
  • Patients who didn't come for follow up.
  • Age less than 14 or more than 50.
  • Unsafe CSOM with cholesteatoma, apparent retraction pockets, granulations, or extensive myringosclerosis reaching the edges of the perforation. Patients
  • Patients who are suspected of having Eustachian tube dysfunction.
  • Suspected ossicular pathology in safe CSOM if the ABG > 40dB.
  • Patients with history of Previous ear surgery.
  • Patients unfit for surgery or having chronic medical illness.
  • Narrow external auditory canal.
  • Patients who refused to enrolled in our study
  • Patients with sensorineural hearing loss or only functioning ear.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    HA group or group A

    * All patients underwent operations under general anesthesia. A single surgeon will perform all surgeries. * A small incision in the rim of ear lobule on the same side of the operated ear, a small piece of adipose tissue will be removed according to the experience of the surgeon. * The incision will be closed with vicryl 4/0 sutures. * Using 0 angulation endoscope visualization, the edges of the perforation will be refreshed and deepithelialized with a sharp Rosen's needle or sickle knife. * sponge gel (Gelfoam) will pushed through TM perforation into the middle ear to support the graft and to avoid its medialization. The previously removed fat graft will be inserted through the perforation adjusted so most of the fat piece lying medial to the perforation and small part laterally. HA was used in liquid form, using a 2 mL vial (® Hyalgan) containing 20 mg of sodium hyaluronate that is synthesized by fermentation. The vial will be prepared for direct injection.

    Procedure: enoscopic Myringoplasty

  • Experimental
    PRP group or group B

    * All patients underwent operations under general anesthesia. A single surgeon will perform all surgeries. * A small incision in the rim of ear lobule on the same side of the operated ear, a small piece of adipose tissue will be removed according to the experience of the surgeon. * The incision will be closed with vicryl 4/0 sutures. * Using 0 angulation endoscope visualization, the edges of the perforation will be refreshed and deepithelialized with a sharp Rosen's needle or sickle knife. * sponge gel (Gelfoam) will pushed through TM perforation into the middle ear to support the graft and to avoid its medialization The previously removed fat graft will be inserted through the perforation adjusted so most of the fat piece lying medial to the perforation and small part laterally PRPG was inserted into the external auditory canal (EAC) on the outer face of the TM remnant and fat graft. Special attention will be given to obtaining close contact among the PRPG, TM, and fat graft. The

    Procedure: enoscopic Myringoplasty

Interventions

  • Procedureenoscopic Myringoplasty

    general anesthesia. A single surgeon will perform all surgeries. * A small incision in the rim of ear lobule on the same side of the operated ear, a small piece of adipose tissue will be removed according to the experience of the surgeon. * Using 0 angulation endoscope visualization, the edges of the perforation will be refreshed and deepithelialized with a sharp Rosen's needle * sponge gel (Gelfoam) will pushed through TM perforation into the middle ear to support the graft and to avoid its medialization * the previously removed fat graft will be inserted through the perforation adjusted so most of the fat piece lying medial to the perforation and small part laterally in patients group A: 0.5 mL of HA vial will be injected directly over the fat graft and the TM remnant. After 5 minutes small gelfoam pieces soaked in 0.5 mL of HA vial will applied over the fat in patients group B PRPG was inserted into the external auditory canal on the outer face of the TM remnant and fat

06

What researchers measure

Primary outcomes

  1. graft taking

    Endoscopic examination of TM: Graft will considered as successfully taken if there is no residual TM perforation after 3 months postoperativly.

    Time frame: 3 months

Secondary outcomes

  1. Audiotympanogram

    effect on hearing by using Audiotympanogram will be done three months post-operative

    Time frame: 3 months

  2. Otorrhea

    presence or absence of otorrhea by history and ear examination

    Time frame: 1 month

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • El-Anwar MW, El-Ahl MA, Zidan AA, Yacoup MA. Topical use of autologous platelet rich plasma in myringoplasty. Auris Nasus Larynx. 2015 Oct;42(5):365-8. doi: 10.1016/j.anl.2015.02.016. Epub 2015 Mar 17. PubMed 25794691 ↗
  • Knutsson J, Kahlin A, von Unge M. Clinical and audiological short-term and long-term outcomes of fat graft myringoplasty. Acta Otolaryngol. 2017 Sep;137(9):940-944. doi: 10.1080/00016489.2017.1326063. Epub 2017 May 24. PubMed 28537107 ↗
  • Kim HC, Park KS, Yang HC, Jang CH. Surgical results and factors affecting outcome in patients with fat-graft myringoplasty. Ear Nose Throat J. 2024 Jul;103(7):442-446. doi: 10.1177/01455613211063243. Epub 2021 Dec 9. PubMed 34881650 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06505252
Lead sponsor
Assiut University
Responsible party
Ahmed Gamal Abdel-Hameed (assistant lecture of otolaryngeology, Assiut University) — Principal investigator
First posted
Jul 17, 2024
Start date
Aug 30, 2024 (estimated)
Primary completion
Jul 9, 2026 (estimated)
Completion
Oct 10, 2026 (estimated)
Last update
Jul 17, 2024

Study contacts

Ahmed Gamal Ahmed Gamal Abdel-Hameed, Assistant lecture
Contact
jamal1991989@gmail.com
00201063211000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion